NZ562805A - Process for the preparation of amorphous fluvastatin sodium - Google Patents
Process for the preparation of amorphous fluvastatin sodiumInfo
- Publication number
- NZ562805A NZ562805A NZ562805A NZ56280504A NZ562805A NZ 562805 A NZ562805 A NZ 562805A NZ 562805 A NZ562805 A NZ 562805A NZ 56280504 A NZ56280504 A NZ 56280504A NZ 562805 A NZ562805 A NZ 562805A
- Authority
- NZ
- New Zealand
- Prior art keywords
- residue
- fluvastatin
- sodium
- methanol
- fluvastatin sodium
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to a process for the preparation of the HMG-CoA reductase inhibitor, fluvastatin, more specifically to a process for the preparation of amorphous form of fluvastatin sodium, wherein the process comprises: (a) dissolving the sodium fluvastatin in methanol followed by stirring, (b) filtering the solution obtained from step (a) over a celite bed, (c) concentrating the methanol extract to get a residue, (d) isolating the residue to get amorphous form of fluvastatin sodium; and (e) optionally subjecting the isolated amorphous form of fluvastatin sodium to drying.
Description
New Zealand Paient Spedficaiion for Paient Number 562805
Process for the preparation of amorphous Fluvastatin sodium
FIELD OF THE INVENTION
The instant invention relates to a novel process for the preparation of the HMG-CoA reductase inhibitor, fluvastatin, more specifically to a process for the preparation of amorphous fluvastatin sodium.
BACKGROUND OF THE INVENTION
Fluvastatin, of which the full chemical name is R*, S*-(E)-(. 7-[3-(4-fluorophenyl)-l-(l-methyl-ethyl)-lH-indol-2-yl]-3,5- dihydroxy-6-heptenoic acid, as well as its sodium salt, are disclosed in EP-A-0 114 027. Fluvastatin is an inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, which is a key enzyme in the regulation of cholesterol biosynthesis. Fluvastatin can be used pharmaceutically particularly as a hypercholesterolemic, hyperlipoproteinemic and antiatherosclerotic agent.
The present invention relates to a novel process for the preparation fluvastatin form A. Polymorphism is the existence of more than one crystal structure for a compound. Since properties can and do vary with crystal structure, polymorphism can influence many important properties of pharamceuticals: bioavailability, dissolution rate, compressibility, solubility, stability, filtering and drying characteristics etc. Different combination of experimental techniques (microscopy, variable temperature X-ray structure determination, spectroscopic and calorimetric methods) are used to discover, prepare, characterize, and study polymorphs of compounds of pharamceutical importance.
Many pharmaceutical materials exhibit polymorphism during heating and this refers to the generation of thermodynamically unstable i
melting forms. These polymorphic forms can be produced due to the given thermal history of the material. Different polymorphic forms can have differing solubilities and this can have a potentially major effect on the bioavailability of the drug when ingested. One polymorphic form may dissolve rapidly while another is very slow to dissolve. It is essential to screen pharmaceuticals for polymorphism for process optimization and for quality assurance purposes.
Fluvastatin sodium is specifically claimed as a substance in patent US 5,354,772.
Polymorphic forms of Fluvastatin sodium are claimed in various patent applications viz. WO 97/49681, WO 02/36563 and WO 03/013512.
WO 97/49681 (equivalent patents US 6,124,340 and EP 0 907 639) claims fluvastatin sodium crystalline form B. The PCT publication has compared properties of form B with form A. In accordance to WO 97/49681, the form A could be obtained by lyophilization process disclosed in U.S. Pat. No. 4,739,073. Several of these prior art process often result in a mixture of amorphous form and different crystalline form.
The present invention provides a robust process for the preparation of fluvastatin sodium in a amorphous form. The amorphous form of fluvastatin sodium thus prepared is substantially free from the anti-isomer.
SUMMARY OF THE INVENTION
The invention relates to a novel process for the preparation of amorphous form of sodium fluvastatin, the process comprising:
(a) dissolving the sodium fluvastatin in methanol followed by stirring,
(b) filtering the solution obtained from step (a) over a celite bed,
(c) concentrating the methanol extract to get a residue, and
(d) isolating the residue to get amorphous form of fluvastatin sodium.
2
INTELLECTUAL PROPERTY OFFICE OF M Z,
2 5 MAY 2009
RECEIVED
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a novel process for the preparation of the HMG-CoA reductase inhibitor, fluvastatin, more specifically to a process for the preparation of amorphous form of fluvastatin sodium.
The instant invention discloses a process for the preparation of amorphous form of fluvastatin sodium comprising of:
(a) dissolving the sodium fluvastatin in methanol followed by stirring,
(b) concentrating the methanol extract to get a residue,
(c) isolating the residue to get amorphous form of fluvastatin sodium.
The process further comprising of
(d) subjecting the isolated amorphous form of fluvastatin sodium to drying.
The process where the amorphous fluvastatin sodium in step (c) is isolated by filtration.
The process where the amorphous form of fluvastatin sodium is vacuum dried.
The instant invention has following advantages over prior art:
1. The process is robust resulting in amorphous form only.
2. The product prepared by the process is chemically stable.
3. The process is simple and economic
4. The process is environmentally friendly.
The present invention is further illustrated by the following non-limiting examples.
EXAMPLES
Example 1
Claims (7)
1. A process for the preparation of amorphous form of fluvastatin sodium comprising: (a) dissolving the sodium fluvastatin in methanol followed by stirring, (b) filtering the solution obtained from step (a) over a celite bed, (c) concentrating the methanol extract to get a residue, and (d) isolating the residue to get amorphous form of fluvastatin sodium.
2. A process of claim 1, further comprising - subjecting the isolated amorphous form of fluvastating sodium to drying.
3. A process of claim 1 or 2, wherein the residue of step (c) is optionally dried under vacuum to get amorphous fluvastatin sodium.
4. A process of any one of claims 1 to 3, wherein the amorphous fluvastatin sodium in step (d) is isolated by filtration.
5. A process of claim 2, wherein the amorphous form of fluvastatin sodium is vacuum dried.
6. A process of claim 1, substantially as herein described with reference to Example 1 or 2.
7. A process of any one of claims 1 to 5, substantially as herein described. 5 INTELLECTUAL PROPERTY OFPIOF OF N Z 2 5 MAY 2009 RECEIVED
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ562805A NZ562805A (en) | 2004-10-05 | 2004-10-05 | Process for the preparation of amorphous fluvastatin sodium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ562805A NZ562805A (en) | 2004-10-05 | 2004-10-05 | Process for the preparation of amorphous fluvastatin sodium |
PCT/IN2004/000310 WO2006038219A1 (en) | 2004-10-05 | 2004-10-05 | Process for the preparation of amorphous fluvastatin sodium |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ562805A true NZ562805A (en) | 2009-06-26 |
Family
ID=40886344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ562805A NZ562805A (en) | 2004-10-05 | 2004-10-05 | Process for the preparation of amorphous fluvastatin sodium |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ562805A (en) |
-
2004
- 2004-10-05 NZ NZ562805A patent/NZ562805A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009221216A (en) | Crystalline form of atorvastatin | |
EP1790635A2 (en) | Processes for preparing amorphous fluvastatin sodium | |
SK5192002A3 (en) | Process for the preparation of amorphous atorvastatin calcium | |
IL195344A (en) | Methods of preparing salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide | |
EP2161257A1 (en) | Amorphous form of an L-arginine salt of perindopril and processes for preparation thereof | |
EP1732886B1 (en) | Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin | |
US8115013B2 (en) | Process for the preparation of amorphous fluvastatin sodium | |
US20090099370A1 (en) | Crystalline Form of Perindopril Erbumine | |
US6326501B1 (en) | Methylation of indole compounds using dimethyl carbonate | |
US20040063961A1 (en) | Crystalline forms of cerivastatin sodium | |
NZ562805A (en) | Process for the preparation of amorphous fluvastatin sodium | |
JPH11292844A (en) | Production of optically active indolin-2-carboxylic acid or its derivative | |
WO2013098773A1 (en) | Crystalline forms of pitavastatin calcium | |
EA007393B1 (en) | Process for preparation of carvedilol | |
US5973165A (en) | Process for preparing 2-oxindole | |
JP2010132561A (en) | New type a crystal of cibenzoline succinate and method for producing the same | |
WO2006021967A1 (en) | Process for the preparation of fluvastatin sodium form a. | |
AU2005329237A1 (en) | An improved process for the purification of perindopril | |
EP2419407B1 (en) | Improved process for the preparation of fluvastatin and salts thereof | |
WO2004096765A2 (en) | A novel crystalline polymorph of fluvastatin sodium and a process for preparing it | |
JP3256208B2 (en) | Method for producing 2-oxindole | |
JP2010538971A (en) | Method for producing valsartan salt effective for producing valsartan | |
RU2439056C1 (en) | Method of obtaining derivatives of 2-aryl(hetaryl)-1h-indoles | |
WO2009008009A1 (en) | Novel crystalline form b of carvedilol dihydrogen phosphate | |
JP2007204460A (en) | Method for producing indole-carboxylic acid esters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENP | Pct: late entry into national phase requested |
Effective date: 20071025 |
|
LENP | Pct: late entry into national phase granted |
Effective date: 20071025 |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2015 BY COMPUTER PACKAGES INC Effective date: 20140918 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 OCT 2016 BY COMPUTER PACKAGES INC Effective date: 20151020 |
|
LAPS | Patent lapsed |